Compare Summit Therapeutics Inc (SMMT) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Suncor Energy Inc. — how do they compare? Summit Therapeutics Inc trades at $14.58 (market cap $10.48B), while Suncor Energy Inc. trades at $63.69 (market cap $72.86B). The key difference: Suncor Energy Inc. is far larger — about 7× Summit Therapeutics Inc's market cap, and Suncor Energy Inc. pays a 2.71% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | SU | |
|---|---|---|
Market Cap | $10.48B | $72.86B |
Sector | Health | Energy |
52-Week High | $29.32 | $69.73 |
52-Week Low | $13.05 | $38.17 |
Enterprise Value | $9.90B | $80.99B |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Suncor Energy (SU) trades at $63.70, up 2.03% today, with a bullish technical signal from moving averages. The company reported mixed Q1 2026 earnings, missing EPS estimates, but beat in the prior two quarters. Valuation ratios appear reasonable with a P/E of 16.8 and EV/EBITDA of 7.08. Strong profitability is evident with a net income margin of 11.62% and ROE of 13.97%. A dividend of $0.60 per share is scheduled for payment on June 25, 2026.
The outlook for SU is supported by record production and integrated operations, but faces risks from oil price volatility and operational incidents. Analyst consensus is strongly bullish with 74% buy ratings. The stock's performance hinges on upcoming Q2 2026 results and broader energy market trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
